Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
Status:
Withdrawn
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
Hidradenitis Suppurativa (HS) is a severe, chronic debilitating disease with a variable and
incomplete response to current treatments. Existing immunological studies have found
dysregulation in the TH17:Treg axis with an increase in inflammatory mediators including
TNFalpha, IL-17 IL-23 (amongst others) in lesional skin. Multiple cell typesincluding CD4+
cells, dendritic cells and macrophages infiltrate active lesions of HS and produce this major
contribution from the Th17 axis.
One of the main barriers to the development of novel and effective treatments for HS is the
lack of biomarker(s) of disease activity, as well as our incomplete understanding of the
pathogenesis of this disease. Given the pronounced contribution of Th17 pathway (including
interleukin-23) in the inflammation in HS, further investigation into the role of this axis
in the pathogenicity of HS is essential. Guselkumab is a fully human interluekin-23
antagonist, FDA approved for the treatment of moderate to severe psoriasis in participants 18
years and over. Guselkumab is a novel potential therapy.